



Schering Sales Corporation

2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530
Telephone (908) 298-4000

IMPORTANT DRUG WARNING

Dear Health Professional:

This letter is to inform you about recent changes to the safety information in the product labeling for INTRON[®] A (Interferon alfa 2b, recombinant) for Injection and REBETRON[®] Combination Therapy containing REBETOL[®] (Ribavirin, USP) Capsules and INTRON[®] A. The change includes the addition of a boxed warning for neuropsychiatric, autoimmune, ischemic, and infectious disorders in patients taking INTRON[®] A. The revised warning also includes specific requirements for monitoring patients for these life-threatening adverse events. This warning has been added to the product information for all alpha interferons. The new labeling includes the following boxed warning:

WARNING

Alpha interferons, including INTRON[®] A, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many but not all cases these disorders resolve after stopping INTRON A therapy. See **WARNINGS**, and **ADVERSE REACTIONS**.


You can further our understanding of adverse events by reporting all adverse events suspected to be associated with the use of INTRON[®] A or REBETRON[®] Combination Therapy to Schering Corporation at 1-800-437-4089. Alternatively, this information may be reported to the FDA's MedWatch program by phone at 1-800-FDA-1088, by facsimile at 1-800-FDA-0178, on line at www.fda.gov/medwatch, or by mail using the postage-paid form FDA 3500, to MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787.

Additional questions concerning INTRON® A or REBETRON® Combination Therapy should be directed to Schering's Drug Information Services at 1-800-526-4099.

This information is provided to you by Schering Corporation as part of our commitment to provide you with the most current product information available.

Please see the enclosed full Prescribing Information for INTRON® A and REBETRON® Combination Therapy.

Sincerely,

A handwritten signature in black ink, appearing to read "J. Garaud", enclosed within a hand-drawn oval shape.

Jean-Jacques Garaud, M.D.
Executive Vice President
Worldwide Clinical
Research & Clinical Operations/RIS